Krystal Biotech reports Q2 2023 net loss $33.2M; VYJUVEK launch yields 121 patient start forms

Krystal Biotech, Inc.

2023-Q1 EPS reported -$3.00

VYJUVEK approved May 19; 121 Patient Start Forms submitted in first six weeks of launch.
Cash, cash equivalents and investments $505.9M as of June 30, 2023.
Net loss $33.2M ($1.25 per share) vs $28.1M ($1.10 per share) in Q2 2022.
First CF patient dosed with KB407 in Phase 1 trial; KB707 IND accepted with Fast Track designation.
Positive coverage from UnitedHealthcare and other national/regional health plans for VYJUVEK.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Krystal Biotech, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 7, 2023, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Krystal Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001711279-23-000067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.